AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone ...
Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data generated using its ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top ...
When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results